Perspectives of Stem Cell-Based Therapy for Age-Related Retinal Degenerative Diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F17%3A00478187" target="_blank" >RIV/68378041:_____/17:00478187 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11310/17:10366586

Výsledek na webu

<a href="http://dx.doi.org/10.3727/096368917X695317" target="_blank" >http://dx.doi.org/10.3727/096368917X695317</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3727/096368917X695317" target="_blank" >10.3727/096368917X695317</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Perspectives of Stem Cell-Based Therapy for Age-Related Retinal Degenerative Diseases

Popis výsledku v původním jazyce

Retinal degenerative diseases, which include age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and glaucoma, mostly affect the elderly population and are the most common cause of decreased quality of vision or even blindness. So far, there is no satisfactory treatment protocol to prevent, stop, or cure these disorders. A great hope and promise for patients suffering from retinal diseases is represented by stem cell-based therapy that could replace diseased or missing retinal cells and support regeneration. In this respect, mesenchymal stem cells (MSCs) that can be obtained from the particular patient and used as autologous cells have turned out to be a promising stem cell type for treatment. Here we show that MSCs can differentiate into cells expressing markers of retinal cells, inhibit production of pro-inflammatory cytokines by retinal tissue, and produce a number of growth and neuroprotective factors for retinal regeneration. All of these properties make MSCs a prospective cell type for cell-based therapy of age-related retinal degenerative diseases.

Název v anglickém jazyce

Perspectives of Stem Cell-Based Therapy for Age-Related Retinal Degenerative Diseases

Popis výsledku anglicky

Retinal degenerative diseases, which include age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and glaucoma, mostly affect the elderly population and are the most common cause of decreased quality of vision or even blindness. So far, there is no satisfactory treatment protocol to prevent, stop, or cure these disorders. A great hope and promise for patients suffering from retinal diseases is represented by stem cell-based therapy that could replace diseased or missing retinal cells and support regeneration. In this respect, mesenchymal stem cells (MSCs) that can be obtained from the particular patient and used as autologous cells have turned out to be a promising stem cell type for treatment. Here we show that MSCs can differentiate into cells expressing markers of retinal cells, inhibit production of pro-inflammatory cytokines by retinal tissue, and produce a number of growth and neuroprotective factors for retinal regeneration. All of these properties make MSCs a prospective cell type for cell-based therapy of age-related retinal degenerative diseases.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30207 - Ophthalmology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cell Transplantation

ISSN

0963-6897

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

1538-1541

Kód UT WoS článku

000414907000006

EID výsledku v databázi Scopus

2-s2.0-85034031933